Acrivon Therapeutics, Inc. ( (ACRV) ) has issued an announcement.
On March 14, 2025, Acrivon Therapeutics announced the appointment of Adam Levy, Ph.D., M.B.A., as Chief Financial Officer effective April 1, 2025. Dr. Levy brings over 25 years of experience in finance and investor relations within the biopharma sector, having previously held senior roles at companies like Zentalis Pharmaceuticals and Gilead Sciences. His appointment follows the departure of Rasmus Holm-Jorgensen, who is stepping down for personal reasons to pursue an opportunity in Europe. This leadership change is not due to any disagreements within the company, and it is expected to strengthen Acrivon’s financial strategy and investor relations.
More about Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. operates within the biopharma industry, focusing on developing therapies for cancer treatment. The company is engaged in advancing precision oncology through its proprietary technology and drug development programs.
YTD Price Performance: -10.90%
Average Trading Volume: 53,819
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $166M
See more data about ACRV stock on TipRanks’ Stock Analysis page.